|Systematic (IUPAC) name|
Diphtheria toxin-Interleukin-2 fusion protein
|Biological half-life||70-80 min|
|CAS Registry Number|
|Molecular mass||57647.3 g/mol|
|(what is this?)|
Denileukin diftitox (trade name Ontak) is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. This can bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these.
A recent study at the University of Louisville found the drug caused many stage IV cutaneous T-cell lympomas to regress or stabilize extending patient life expectancy from about eight months to more than a year; a clinically significant increase especially given the guarded prognosis of patients with advanced disseminated cutaneous T-cell lymphoma (CTCL) and the generally poor response to other available treatments.
- Turturro F (2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Rev Anticancer Ther 7 (1): 11–7. doi:10.1586/1473722.214.171.124. PMID 17187516.
- FDA Page Last Updated: May 11, 2009 Changes in the Ontak (denileukin diftitiox) Package Insert to Include a Description of Ophthalmologic Adverse Events
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|